Resurfacing Treatment Pads
Over-the-Counter상품명: AHA/BHA Swipes
About This Medication
Topical product applied to the skin for localized treatment and symptom relief.
유효 성분
| 성분 | 함량 |
|---|---|
| Salicylic Acid | - |
적응증 및 용법
용량 및 투여 방법
경고 및 주의 사항
Warnings For external use only When using this product Skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time.If irritation occurs, only use one topical acne medication at a time. Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away.
Frequently Asked Questions
Use For the management of acne
Directions • after cleansing, use one (1) pad to sweep over dry face with focus on acne-prone areas of the skin • Can be used up to two times daily or as tolerated by skin • Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor • If bothersome dryness or peeling occurs, reduce application to once a day or …
Warnings For external use only When using this product Skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time.If irritation occurs, only use one topical acne medication at a time. Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away.
Resurfacing Treatment Pads is available over the counter (OTC) without a prescription.
Similar Topical Products
Browse all Topical products →References & Data Sources
- • DailyMed — Resurfacing Treatment Pads drug label (National Library of Medicine)
- • openFDA — Resurfacing Treatment Pads label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 797892 (NLM Normalized Drug Names)
- • NDC Directory — Resurfacing Treatment Pads (FDA National Drug Code)
의료 면책 조항
이 페이지의 정보는 교육 목적으로만 제공되며, 전문적인 의학적 조언, 진단 또는 치료를 대체하는 용도로 사용해서는 안 됩니다.
의학적 상태나 의약품에 관한 질문이 있으시면 반드시 의사 또는 자격을 갖춘 의료 전문가에게 조언을 구하시기 바랍니다.
데이터 출처: DailyMed (NLM), openFDA, MFDS